Vestal Point Capital LP Buys 410,000 Shares of Ventyx Biosciences, Inc. (NASDAQ:VTYX)

Vestal Point Capital LP increased its position in Ventyx Biosciences, Inc. (NASDAQ:VTYX) by 31.2% during the 3rd quarter, Holdings Channel reports. The firm owned 1,725,000 shares of the company’s stock after acquiring an additional 410,000 shares during the quarter. Vestal Point Capital LP’s holdings in Ventyx Biosciences were worth $3,760,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently bought and sold shares of the company. Palumbo Wealth Management LLC purchased a new stake in Ventyx Biosciences in the third quarter worth about $26,000. China Universal Asset Management Co. Ltd. lifted its position in shares of Ventyx Biosciences by 64.1% in the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 13,592 shares of the company’s stock worth $30,000 after purchasing an additional 5,310 shares during the period. SG Americas Securities LLC purchased a new stake in shares of Ventyx Biosciences in the 2nd quarter worth approximately $32,000. Intech Investment Management LLC bought a new position in shares of Ventyx Biosciences during the third quarter valued at approximately $42,000. Finally, The Manufacturers Life Insurance Company increased its holdings in Ventyx Biosciences by 41.1% during the second quarter. The Manufacturers Life Insurance Company now owns 24,349 shares of the company’s stock valued at $56,000 after buying an additional 7,096 shares during the period. Institutional investors own 97.88% of the company’s stock.

Analyst Ratings Changes

A number of research analysts have recently issued reports on VTYX shares. Wells Fargo & Company cut their price target on Ventyx Biosciences from $16.00 to $11.00 and set an “overweight” rating on the stock in a report on Monday, August 12th. Canaccord Genuity Group cut their target price on Ventyx Biosciences from $15.00 to $14.00 and set a “buy” rating on the stock in a research note on Monday, August 12th. HC Wainwright reissued a “neutral” rating and set a $6.00 price target on shares of Ventyx Biosciences in a research report on Monday, November 11th. Finally, Oppenheimer reaffirmed an “outperform” rating and issued a $9.00 price objective (down previously from $10.00) on shares of Ventyx Biosciences in a research report on Friday, November 8th. One investment analyst has rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $10.00.

Insider Buying and Selling

In related news, CEO Raju Mohan acquired 261,752 shares of Ventyx Biosciences stock in a transaction on Monday, November 25th. The stock was acquired at an average price of $2.01 per share, for a total transaction of $526,121.52. Following the purchase, the chief executive officer now owns 2,175,028 shares of the company’s stock, valued at approximately $4,371,806.28. This represents a 13.68 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 18.18% of the company’s stock.

Ventyx Biosciences Price Performance

Shares of VTYX stock opened at $2.65 on Friday. The business has a fifty day moving average of $2.20 and a 200 day moving average of $2.62. Ventyx Biosciences, Inc. has a 1 year low of $1.67 and a 1 year high of $11.48. The firm has a market capitalization of $187.38 million, a price-to-earnings ratio of -1.12 and a beta of 0.37.

Ventyx Biosciences Company Profile

Ventyx Biosciences, Inc, a clinical-stage biopharmaceutical company, develops small molecule product candidates to address a range of inflammatory diseases. The company’s lead clinical product candidate is VTX958, a selective allosteric tyrosine kinase type 2 inhibitor for psoriasis, psoriatic arthritis, and Crohn’s disease.